Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is seeing a sharp pullback in Tuesday trading (Dec. 16, 2025), with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76. That drop may look dramatic in isolation, but it’s landing on top of an unusually eventful stretch for the RNA interference (RNAi) biotech: Arrowhead just transitioned into a commercial-stage story after its first FDA approval, picked up an FDA Breakthrough Therapy designation for a follow-on indication, and kicked off a new Alzheimer’s-related clinical program—three ingredients that tend to increase both upside narratives and day-to-day volatility